 Jon Matsumura
Concepts (459)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Vessel Prosthesis Implantation | 84 | 2024 | 197 | 15.630 |
Why?
| | Aortic Aneurysm, Abdominal | 67 | 2024 | 132 | 11.700 |
Why?
| | Blood Vessel Prosthesis | 57 | 2024 | 123 | 10.790 |
Why?
| | Endovascular Procedures | 49 | 2024 | 301 | 10.620 |
Why?
| | Stents | 66 | 2024 | 504 | 7.940 |
Why?
| | Aortic Aneurysm, Thoracic | 32 | 2024 | 127 | 7.690 |
Why?
| | Aorta, Thoracic | 25 | 2024 | 263 | 4.530 |
Why?
| | Carotid Stenosis | 23 | 2024 | 84 | 3.940 |
Why?
| | Prosthesis Design | 38 | 2024 | 309 | 3.580 |
Why?
| | Iliac Aneurysm | 9 | 2024 | 19 | 3.520 |
Why?
| | Vascular Surgical Procedures | 19 | 2018 | 295 | 2.650 |
Why?
| | Endarterectomy, Carotid | 14 | 2024 | 47 | 2.410 |
Why?
| | Vascular System Injuries | 6 | 2024 | 73 | 2.260 |
Why?
| | Aortography | 17 | 2024 | 51 | 2.230 |
Why?
| | Tomography, X-Ray Computed | 36 | 2024 | 2511 | 2.230 |
Why?
| | Treatment Outcome | 93 | 2024 | 10241 | 2.090 |
Why?
| | Iliac Artery | 11 | 2024 | 55 | 1.940 |
Why?
| | Computed Tomography Angiography | 8 | 2024 | 115 | 1.930 |
Why?
| | Angioplasty | 12 | 2017 | 47 | 1.920 |
Why?
| | Aortic Diseases | 8 | 2019 | 114 | 1.850 |
Why?
| | Time Factors | 54 | 2024 | 6550 | 1.720 |
Why?
| | Stroke | 18 | 2024 | 1072 | 1.650 |
Why?
| | Aortic Aneurysm | 9 | 2024 | 66 | 1.650 |
Why?
| | Aortic Rupture | 12 | 2022 | 25 | 1.600 |
Why?
| | Aged, 80 and over | 54 | 2024 | 7066 | 1.500 |
Why?
| | Angioplasty, Balloon | 9 | 2013 | 92 | 1.460 |
Why?
| | Aged | 101 | 2024 | 22107 | 1.410 |
Why?
| | Postoperative Complications | 33 | 2024 | 2481 | 1.250 |
Why?
| | Sarcopenia | 2 | 2019 | 74 | 1.150 |
Why?
| | Risk Factors | 41 | 2024 | 9801 | 1.120 |
Why?
| | Endoleak | 10 | 2024 | 16 | 1.070 |
Why?
| | Prosthesis Failure | 11 | 2017 | 114 | 1.030 |
Why?
| | Middle Aged | 77 | 2024 | 31177 | 1.010 |
Why?
| | Aorta, Abdominal | 8 | 2024 | 43 | 0.990 |
Why?
| | Humans | 176 | 2024 | 129847 | 0.960 |
Why?
| | Prospective Studies | 35 | 2024 | 7158 | 0.960 |
Why?
| | Subclavian Artery | 6 | 2022 | 28 | 0.960 |
Why?
| | Male | 116 | 2024 | 63759 | 0.930 |
Why?
| | Vascular Patency | 12 | 2021 | 102 | 0.920 |
Why?
| | Myocardial Infarction | 5 | 2024 | 1021 | 0.870 |
Why?
| | United States | 39 | 2024 | 13913 | 0.860 |
Why?
| | Female | 109 | 2024 | 68829 | 0.830 |
Why?
| | Femoral Artery | 4 | 2013 | 174 | 0.800 |
Why?
| | Vena Cava Filters | 5 | 2023 | 60 | 0.780 |
Why?
| | Predictive Value of Tests | 10 | 2024 | 1951 | 0.770 |
Why?
| | Ulcer | 3 | 2014 | 28 | 0.730 |
Why?
| | Risk Assessment | 21 | 2024 | 3269 | 0.730 |
Why?
| | Population Surveillance | 2 | 2021 | 439 | 0.720 |
Why?
| | Foreign-Body Migration | 3 | 2017 | 34 | 0.670 |
Why?
| | Retrospective Studies | 43 | 2024 | 14553 | 0.670 |
Why?
| | Ischemia | 5 | 2018 | 405 | 0.650 |
Why?
| | Alloys | 3 | 2024 | 34 | 0.650 |
Why?
| | Frailty | 2 | 2019 | 152 | 0.630 |
Why?
| | Reoperation | 13 | 2020 | 542 | 0.630 |
Why?
| | Peripheral Arterial Disease | 2 | 2018 | 458 | 0.620 |
Why?
| | Popliteal Artery | 4 | 2015 | 58 | 0.620 |
Why?
| | Psoas Muscles | 1 | 2018 | 9 | 0.620 |
Why?
| | Marfan Syndrome | 1 | 2019 | 39 | 0.610 |
Why?
| | Body Composition | 2 | 2019 | 649 | 0.580 |
Why?
| | Societies, Medical | 5 | 2020 | 759 | 0.570 |
Why?
| | Chlorhexidine | 1 | 2017 | 23 | 0.540 |
Why?
| | Decontamination | 1 | 2017 | 24 | 0.540 |
Why?
| | Anti-Infective Agents, Local | 1 | 2017 | 41 | 0.530 |
Why?
| | Health Care Costs | 3 | 2014 | 367 | 0.530 |
Why?
| | Elective Surgical Procedures | 8 | 2020 | 165 | 0.520 |
Why?
| | Doxycycline | 3 | 2023 | 59 | 0.500 |
Why?
| | Wounds, Nonpenetrating | 6 | 2024 | 273 | 0.500 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 207 | 0.490 |
Why?
| | Infection Control | 1 | 2017 | 143 | 0.490 |
Why?
| | Radiography, Interventional | 5 | 2019 | 105 | 0.480 |
Why?
| | Thoracic Injuries | 3 | 2024 | 55 | 0.470 |
Why?
| | Follow-Up Studies | 26 | 2024 | 4896 | 0.470 |
Why?
| | Education, Medical, Continuing | 2 | 2014 | 123 | 0.460 |
Why?
| | Patient Readmission | 3 | 2014 | 668 | 0.440 |
Why?
| | Lower Extremity | 1 | 2018 | 407 | 0.440 |
Why?
| | Program Development | 2 | 2014 | 355 | 0.440 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 283 | 0.430 |
Why?
| | Vascular Diseases | 2 | 2014 | 240 | 0.420 |
Why?
| | Kaplan-Meier Estimate | 10 | 2019 | 851 | 0.410 |
Why?
| | Health Expenditures | 1 | 2014 | 180 | 0.400 |
Why?
| | Congresses as Topic | 1 | 2014 | 216 | 0.400 |
Why?
| | Carotid Artery Diseases | 3 | 2005 | 64 | 0.400 |
Why?
| | Patient Selection | 7 | 2021 | 660 | 0.390 |
Why?
| | Skin | 1 | 2017 | 725 | 0.380 |
Why?
| | Asymptomatic Diseases | 5 | 2024 | 84 | 0.380 |
Why?
| | Embolic Protection Devices | 1 | 2012 | 12 | 0.370 |
Why?
| | Constriction, Pathologic | 7 | 2023 | 234 | 0.360 |
Why?
| | Minimally Invasive Surgical Procedures | 7 | 2009 | 175 | 0.360 |
Why?
| | Arterial Occlusive Diseases | 3 | 2008 | 80 | 0.350 |
Why?
| | Pulmonary Embolism | 2 | 2005 | 212 | 0.350 |
Why?
| | Ultrasonography, Interventional | 3 | 2001 | 130 | 0.350 |
Why?
| | Thoracic Outlet Syndrome | 3 | 2001 | 15 | 0.350 |
Why?
| | Thromboembolism | 1 | 2012 | 112 | 0.350 |
Why?
| | Severity of Illness Index | 9 | 2024 | 2739 | 0.340 |
Why?
| | Intracranial Embolism | 1 | 2010 | 31 | 0.340 |
Why?
| | Ultrasonography, Doppler, Duplex | 10 | 2017 | 43 | 0.340 |
Why?
| | Disease Progression | 6 | 2023 | 2628 | 0.340 |
Why?
| | Filtration | 1 | 2010 | 67 | 0.330 |
Why?
| | Adult | 37 | 2024 | 35634 | 0.330 |
Why?
| | Peripheral Vascular Diseases | 2 | 2004 | 102 | 0.330 |
Why?
| | Muscle, Skeletal | 1 | 2019 | 1644 | 0.320 |
Why?
| | Venous Thrombosis | 5 | 2005 | 176 | 0.320 |
Why?
| | Radiography | 7 | 2012 | 800 | 0.310 |
Why?
| | Chi-Square Distribution | 5 | 2014 | 515 | 0.300 |
Why?
| | Thrombosis | 4 | 2018 | 349 | 0.290 |
Why?
| | Survival Rate | 10 | 2016 | 1872 | 0.290 |
Why?
| | Stainless Steel | 2 | 2024 | 21 | 0.290 |
Why?
| | Iliac Vein | 2 | 2006 | 11 | 0.290 |
Why?
| | Regional Blood Flow | 4 | 2018 | 463 | 0.290 |
Why?
| | Paraparesis | 2 | 2008 | 6 | 0.270 |
Why?
| | Spinal Cord Ischemia | 2 | 2010 | 56 | 0.270 |
Why?
| | Hospitals, University | 1 | 2007 | 180 | 0.260 |
Why?
| | Graft Occlusion, Vascular | 4 | 2018 | 41 | 0.260 |
Why?
| | Hospital Mortality | 4 | 2020 | 852 | 0.250 |
Why?
| | Length of Stay | 6 | 2024 | 1133 | 0.250 |
Why?
| | Health Status | 3 | 2019 | 758 | 0.250 |
Why?
| | Angiography | 5 | 2017 | 197 | 0.250 |
Why?
| | Ankle Brachial Index | 2 | 2018 | 36 | 0.250 |
Why?
| | Epidemiologic Research Design | 1 | 2005 | 27 | 0.240 |
Why?
| | Protein-Lysine 6-Oxidase | 1 | 2024 | 8 | 0.240 |
Why?
| | Amino Acid Oxidoreductases | 1 | 2024 | 19 | 0.230 |
Why?
| | Retreatment | 2 | 2021 | 70 | 0.230 |
Why?
| | Incisional Hernia | 1 | 2024 | 3 | 0.230 |
Why?
| | Erectile Dysfunction | 2 | 2023 | 39 | 0.230 |
Why?
| | Clinical Trials as Topic | 4 | 2019 | 1005 | 0.220 |
Why?
| | Preoperative Care | 3 | 2017 | 337 | 0.210 |
Why?
| | Multicenter Studies as Topic | 3 | 2014 | 287 | 0.210 |
Why?
| | Femoral Vein | 3 | 2001 | 32 | 0.210 |
Why?
| | Matrix Metalloproteinase 3 | 1 | 2023 | 26 | 0.210 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 124 | 0.200 |
Why?
| | Catheterization, Peripheral | 3 | 2009 | 105 | 0.200 |
Why?
| | Comorbidity | 7 | 2019 | 1551 | 0.200 |
Why?
| | Paraplegia | 4 | 2011 | 57 | 0.200 |
Why?
| | Carotid Artery, Internal | 5 | 2008 | 41 | 0.190 |
Why?
| | Equipment Design | 6 | 2011 | 514 | 0.190 |
Why?
| | Double-Blind Method | 3 | 2023 | 1877 | 0.190 |
Why?
| | Feasibility Studies | 7 | 2022 | 870 | 0.190 |
Why?
| | Prosthesis Implantation | 2 | 2002 | 148 | 0.190 |
Why?
| | Vascular Calcification | 1 | 2023 | 107 | 0.190 |
Why?
| | Aftercare | 2 | 2020 | 206 | 0.190 |
Why?
| | Odds Ratio | 3 | 2014 | 1022 | 0.180 |
Why?
| | Clinical Competence | 6 | 2019 | 1020 | 0.180 |
Why?
| | Registries | 2 | 2019 | 1903 | 0.180 |
Why?
| | Hyperglycemia | 1 | 2024 | 327 | 0.180 |
Why?
| | Reproducibility of Results | 3 | 2018 | 3089 | 0.180 |
Why?
| | Eligibility Determination | 1 | 2021 | 63 | 0.180 |
Why?
| | Patients' Rooms | 1 | 2000 | 12 | 0.170 |
Why?
| | Logistic Models | 4 | 2015 | 1989 | 0.170 |
Why?
| | Collateral Circulation | 2 | 2010 | 18 | 0.170 |
Why?
| | Cause of Death | 4 | 2019 | 395 | 0.170 |
Why?
| | Abdominal Oblique Muscles | 1 | 2019 | 1 | 0.170 |
Why?
| | Intercostal Muscles | 1 | 2019 | 3 | 0.170 |
Why?
| | Superficial Back Muscles | 1 | 2019 | 14 | 0.160 |
Why?
| | Rectus Abdominis | 1 | 2019 | 16 | 0.160 |
Why?
| | Oleic Acids | 1 | 1999 | 10 | 0.160 |
Why?
| | United States Food and Drug Administration | 3 | 2009 | 205 | 0.160 |
Why?
| | Spinal Fusion | 1 | 2022 | 233 | 0.160 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 569 | 0.160 |
Why?
| | Liposomes | 1 | 2000 | 171 | 0.160 |
Why?
| | Specialties, Surgical | 1 | 2020 | 74 | 0.160 |
Why?
| | Credentialing | 1 | 2019 | 16 | 0.160 |
Why?
| | Aneurysm, Ruptured | 2 | 2013 | 34 | 0.160 |
Why?
| | Observer Variation | 2 | 2018 | 314 | 0.150 |
Why?
| | Genetic Therapy | 1 | 2000 | 293 | 0.150 |
Why?
| | Frail Elderly | 1 | 2019 | 120 | 0.150 |
Why?
| | Surgeons | 1 | 2022 | 264 | 0.150 |
Why?
| | Disease-Free Survival | 3 | 2017 | 647 | 0.150 |
Why?
| | Curriculum | 1 | 2005 | 928 | 0.150 |
Why?
| | Phosphatidylcholines | 1 | 1999 | 145 | 0.150 |
Why?
| | Electronic Mail | 1 | 2018 | 60 | 0.150 |
Why?
| | Gene Transfer Techniques | 1 | 1999 | 164 | 0.150 |
Why?
| | Protease Inhibitors | 1 | 2019 | 107 | 0.150 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1708 | 0.150 |
Why?
| | Neck Muscles | 1 | 1997 | 18 | 0.140 |
Why?
| | Limb Salvage | 1 | 2018 | 57 | 0.140 |
Why?
| | Ribs | 1 | 1997 | 34 | 0.140 |
Why?
| | Anatomic Landmarks | 1 | 2017 | 28 | 0.140 |
Why?
| | Clavicle | 1 | 1997 | 33 | 0.140 |
Why?
| | Critical Illness | 3 | 2018 | 759 | 0.140 |
Why?
| | Blood Vessels | 1 | 1999 | 187 | 0.140 |
Why?
| | Administration, Cutaneous | 1 | 2017 | 124 | 0.130 |
Why?
| | Axillary Artery | 1 | 1996 | 12 | 0.130 |
Why?
| | Endothelium, Vascular | 2 | 2000 | 902 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2024 | 1368 | 0.130 |
Why?
| | Bile Pigments | 1 | 1996 | 1 | 0.130 |
Why?
| | Quality Assurance, Health Care | 2 | 2019 | 318 | 0.130 |
Why?
| | Cholagogues and Choleretics | 1 | 1996 | 8 | 0.130 |
Why?
| | Bile | 1 | 1996 | 35 | 0.130 |
Why?
| | Cholelithiasis | 1 | 1996 | 36 | 0.130 |
Why?
| | Incidence | 7 | 2016 | 2646 | 0.120 |
Why?
| | Analysis of Variance | 2 | 2016 | 1291 | 0.120 |
Why?
| | Antioxidants | 1 | 2019 | 558 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 482 | 0.120 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 485 | 0.120 |
Why?
| | Survival Analysis | 6 | 2016 | 1271 | 0.120 |
Why?
| | Blood Glucose | 1 | 2024 | 2103 | 0.120 |
Why?
| | Spinal Injuries | 1 | 1995 | 51 | 0.120 |
Why?
| | Chicago | 3 | 2011 | 57 | 0.110 |
Why?
| | Evidence-Based Medicine | 4 | 2017 | 716 | 0.110 |
Why?
| | Prosthesis-Related Infections | 2 | 2008 | 75 | 0.110 |
Why?
| | Age Factors | 3 | 2024 | 3161 | 0.110 |
Why?
| | Intermittent Claudication | 1 | 2015 | 118 | 0.110 |
Why?
| | Wisconsin | 1 | 2013 | 99 | 0.110 |
Why?
| | Hospital Costs | 1 | 2014 | 115 | 0.110 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 542 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 530 | 0.110 |
Why?
| | Taurocholic Acid | 1 | 1993 | 33 | 0.100 |
Why?
| | Clinical Decision-Making | 3 | 2021 | 304 | 0.100 |
Why?
| | Parenteral Nutrition, Total | 1 | 1993 | 26 | 0.100 |
Why?
| | Gastrointestinal Diseases | 1 | 1995 | 198 | 0.100 |
Why?
| | Hypertension | 2 | 2021 | 1242 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 1003 | 0.100 |
Why?
| | Aneurysm | 2 | 2003 | 31 | 0.100 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 153 | 0.100 |
Why?
| | Postoperative Care | 1 | 2014 | 244 | 0.100 |
Why?
| | Intestinal Absorption | 1 | 1993 | 99 | 0.100 |
Why?
| | Intraoperative Complications | 3 | 2019 | 129 | 0.100 |
Why?
| | Leg | 3 | 1999 | 240 | 0.100 |
Why?
| | Communication | 1 | 2018 | 847 | 0.100 |
Why?
| | Ileum | 1 | 1993 | 116 | 0.100 |
Why?
| | Europe | 1 | 2013 | 363 | 0.100 |
Why?
| | Device Approval | 2 | 2009 | 21 | 0.100 |
Why?
| | Biomarkers | 1 | 2023 | 3971 | 0.090 |
Why?
| | Permeability | 2 | 2009 | 158 | 0.090 |
Why?
| | Catheters | 1 | 2011 | 70 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2009 | 1199 | 0.090 |
Why?
| | Viscera | 1 | 2011 | 16 | 0.090 |
Why?
| | Acute Disease | 4 | 2024 | 980 | 0.090 |
Why?
| | Netherlands | 2 | 2020 | 77 | 0.090 |
Why?
| | Exercise Tolerance | 1 | 2013 | 273 | 0.090 |
Why?
| | Bayes Theorem | 2 | 2023 | 374 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2018 | 979 | 0.090 |
Why?
| | Vertebrobasilar Insufficiency | 1 | 2010 | 8 | 0.090 |
Why?
| | Residence Characteristics | 1 | 2013 | 332 | 0.090 |
Why?
| | Aneurysm, False | 1 | 2011 | 47 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2014 | 509 | 0.090 |
Why?
| | Young Adult | 5 | 2024 | 12467 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2008 | 0.090 |
Why?
| | Databases as Topic | 1 | 2010 | 59 | 0.090 |
Why?
| | Research Design | 3 | 2009 | 1045 | 0.080 |
Why?
| | United States Department of Veterans Affairs | 1 | 2014 | 628 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2724 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1501 | 0.080 |
Why?
| | Exercise Test | 1 | 2013 | 614 | 0.080 |
Why?
| | Anesthesiology | 1 | 1990 | 63 | 0.080 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2009 | 27 | 0.080 |
Why?
| | Ischemic Attack, Transient | 2 | 2009 | 60 | 0.080 |
Why?
| | Hospitals, Urban | 1 | 2010 | 135 | 0.080 |
Why?
| | Telemedicine | 1 | 2018 | 792 | 0.080 |
Why?
| | Radiography, Abdominal | 2 | 2001 | 46 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 1214 | 0.080 |
Why?
| | General Surgery | 2 | 2014 | 152 | 0.080 |
Why?
| | Genes, Reporter | 2 | 2000 | 266 | 0.080 |
Why?
| | Dilatation, Pathologic | 2 | 1999 | 60 | 0.080 |
Why?
| | Porosity | 1 | 2009 | 95 | 0.080 |
Why?
| | Plasmids | 2 | 2000 | 360 | 0.080 |
Why?
| | Benchmarking | 1 | 2010 | 176 | 0.080 |
Why?
| | Extremities | 1 | 2009 | 127 | 0.080 |
Why?
| | Rupture | 1 | 2009 | 92 | 0.080 |
Why?
| | Ultrasonography | 4 | 2014 | 713 | 0.070 |
Why?
| | Aorta | 2 | 2022 | 408 | 0.070 |
Why?
| | Carotid Arteries | 1 | 2010 | 196 | 0.070 |
Why?
| | Coronary Artery Bypass | 2 | 2000 | 224 | 0.070 |
Why?
| | Treatment Failure | 2 | 2020 | 339 | 0.070 |
Why?
| | Animals | 6 | 2024 | 35409 | 0.070 |
Why?
| | Carotid Artery Thrombosis | 1 | 2007 | 7 | 0.070 |
Why?
| | Practice Guidelines as Topic | 5 | 2010 | 1514 | 0.070 |
Why?
| | Organ Size | 2 | 2020 | 456 | 0.070 |
Why?
| | Patient Discharge | 1 | 2013 | 856 | 0.070 |
Why?
| | Equipment Safety | 2 | 2009 | 37 | 0.070 |
Why?
| | Calcinosis | 1 | 2009 | 233 | 0.070 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2004 | 739 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2014 | 900 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2010 | 321 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2062 | 0.060 |
Why?
| | Arm | 2 | 1997 | 107 | 0.060 |
Why?
| | Prostheses and Implants | 1 | 2007 | 135 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2005 | 72 | 0.060 |
Why?
| | Polyesters | 1 | 2006 | 75 | 0.060 |
Why?
| | Hematoma | 1 | 2005 | 53 | 0.060 |
Why?
| | Vena Cava, Inferior | 2 | 2023 | 68 | 0.060 |
Why?
| | Recurrence | 3 | 2017 | 1013 | 0.060 |
Why?
| | Renal Veins | 1 | 2004 | 16 | 0.060 |
Why?
| | Mesenteric Artery, Superior | 1 | 2004 | 15 | 0.060 |
Why?
| | Health Status Indicators | 1 | 2005 | 166 | 0.060 |
Why?
| | United Kingdom | 2 | 2003 | 258 | 0.060 |
Why?
| | Hernia, Ventral | 1 | 2004 | 23 | 0.060 |
Why?
| | Extracellular Matrix Proteins | 1 | 2024 | 144 | 0.050 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2023 | 15 | 0.050 |
Why?
| | Nephrectomy | 1 | 2004 | 158 | 0.050 |
Why?
| | Fluoroscopy | 2 | 2001 | 157 | 0.050 |
Why?
| | Leadership | 1 | 2007 | 361 | 0.050 |
Why?
| | Data Collection | 1 | 2006 | 653 | 0.050 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2024 | 259 | 0.050 |
Why?
| | Vascular Remodeling | 1 | 2024 | 192 | 0.050 |
Why?
| | Cerebrovascular Disorders | 2 | 2000 | 90 | 0.050 |
Why?
| | Lumbosacral Region | 1 | 2022 | 55 | 0.050 |
Why?
| | Head and Neck Neoplasms | 1 | 2007 | 544 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2000 | 4102 | 0.050 |
Why?
| | Illinois | 3 | 2008 | 42 | 0.050 |
Why?
| | Quality of Health Care | 1 | 2007 | 610 | 0.050 |
Why?
| | Delphi Technique | 1 | 2023 | 227 | 0.050 |
Why?
| | Perfusion | 1 | 2023 | 197 | 0.050 |
Why?
| | Learning Curve | 1 | 2022 | 69 | 0.050 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2024 | 444 | 0.050 |
Why?
| | Substance-Related Disorders | 1 | 1990 | 1023 | 0.050 |
Why?
| | Device Removal | 1 | 2023 | 136 | 0.050 |
Why?
| | Mesenteric Vascular Occlusion | 1 | 2001 | 5 | 0.050 |
Why?
| | Time | 1 | 2002 | 77 | 0.050 |
Why?
| | Arteries | 1 | 2023 | 266 | 0.050 |
Why?
| | Health Status Disparities | 1 | 2024 | 256 | 0.050 |
Why?
| | Mesenteric Veins | 1 | 2001 | 18 | 0.050 |
Why?
| | England | 1 | 2001 | 74 | 0.050 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2001 | 7 | 0.050 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 89 | 0.040 |
Why?
| | Biomedical Research | 1 | 2007 | 640 | 0.040 |
Why?
| | Internship and Residency | 1 | 1990 | 1058 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2005 | 1847 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4077 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2001 | 201 | 0.040 |
Why?
| | Gene Targeting | 1 | 2000 | 81 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 622 | 0.040 |
Why?
| | Peritoneum | 1 | 2000 | 41 | 0.040 |
Why?
| | Cerebral Angiography | 1 | 2000 | 108 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 198 | 0.040 |
Why?
| | Radiotherapy | 1 | 2001 | 185 | 0.040 |
Why?
| | Troponin T | 1 | 2000 | 57 | 0.040 |
Why?
| | Intracranial Aneurysm | 1 | 2000 | 95 | 0.040 |
Why?
| | Cation Exchange Resins | 1 | 1999 | 7 | 0.040 |
Why?
| | Injury Severity Score | 2 | 2013 | 509 | 0.040 |
Why?
| | Spermine | 1 | 1999 | 28 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2001 | 1434 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2001 | 149 | 0.040 |
Why?
| | Quality of Life | 4 | 2012 | 2695 | 0.040 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 1999 | 16 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 1 | 2000 | 93 | 0.040 |
Why?
| | Rabbits | 1 | 2000 | 778 | 0.040 |
Why?
| | Emergency Treatment | 1 | 2020 | 114 | 0.040 |
Why?
| | Luciferases | 1 | 1999 | 147 | 0.040 |
Why?
| | Monitoring, Intraoperative | 1 | 1999 | 51 | 0.040 |
Why?
| | Prognosis | 3 | 2015 | 3773 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1274 | 0.040 |
Why?
| | Veins | 1 | 1999 | 60 | 0.040 |
Why?
| | Endoscopy | 1 | 2001 | 290 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 1973 | 0.040 |
Why?
| | Glycine | 1 | 1999 | 166 | 0.040 |
Why?
| | Drug Carriers | 1 | 1999 | 121 | 0.040 |
Why?
| | Postoperative Period | 1 | 1999 | 330 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2000 | 335 | 0.040 |
Why?
| | Arteriosclerosis | 1 | 1998 | 89 | 0.040 |
Why?
| | Subclavian Vein | 1 | 1997 | 15 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 787 | 0.040 |
Why?
| | Surgical Flaps | 1 | 1999 | 136 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 1998 | 150 | 0.030 |
Why?
| | Blood Proteins | 1 | 1999 | 245 | 0.030 |
Why?
| | Multiple Trauma | 2 | 2010 | 101 | 0.030 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 1997 | 29 | 0.030 |
Why?
| | Intraoperative Care | 1 | 1997 | 46 | 0.030 |
Why?
| | Retroperitoneal Neoplasms | 1 | 1997 | 25 | 0.030 |
Why?
| | Transfection | 1 | 1999 | 918 | 0.030 |
Why?
| | Veterans | 1 | 2008 | 1383 | 0.030 |
Why?
| | Hemodynamics | 2 | 2000 | 1094 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5468 | 0.030 |
Why?
| | Cholic Acids | 1 | 1996 | 17 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1311 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 1999 | 503 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 628 | 0.030 |
Why?
| | Anticoagulants | 2 | 2016 | 637 | 0.030 |
Why?
| | Taurine | 1 | 1996 | 43 | 0.030 |
Why?
| | Atherosclerosis | 1 | 2019 | 402 | 0.030 |
Why?
| | Lipids | 1 | 1999 | 628 | 0.030 |
Why?
| | Movement | 1 | 1997 | 270 | 0.030 |
Why?
| | Wound Healing | 1 | 1998 | 308 | 0.030 |
Why?
| | Contrast Media | 1 | 1998 | 394 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2001 | 957 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1999 | 2016 | 0.030 |
Why?
| | Dogs | 1 | 1996 | 385 | 0.030 |
Why?
| | Myocardium | 1 | 2000 | 983 | 0.030 |
Why?
| | Sarcoma | 1 | 1997 | 175 | 0.030 |
Why?
| | Prevalence | 1 | 2001 | 2564 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1998 | 313 | 0.030 |
Why?
| | Bile Acids and Salts | 1 | 1996 | 195 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1999 | 1205 | 0.030 |
Why?
| | Gene Expression | 1 | 1999 | 1465 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1269 | 0.030 |
Why?
| | Mass Screening | 1 | 2001 | 1192 | 0.030 |
Why?
| | Cohort Studies | 3 | 2012 | 5444 | 0.030 |
Why?
| | Accidents, Traffic | 2 | 2005 | 184 | 0.030 |
Why?
| | Swine, Miniature | 1 | 1993 | 81 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 3 | 2003 | 3397 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2012 | 79 | 0.030 |
Why?
| | Blood Flow Velocity | 2 | 2005 | 406 | 0.020 |
Why?
| | DNA | 1 | 1999 | 1406 | 0.020 |
Why?
| | Random Allocation | 1 | 1993 | 347 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 1993 | 402 | 0.020 |
Why?
| | Quality-Adjusted Life Years | 1 | 2012 | 106 | 0.020 |
Why?
| | Case-Control Studies | 2 | 2014 | 3384 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5085 | 0.020 |
Why?
| | Physician Impairment | 1 | 1990 | 8 | 0.020 |
Why?
| | Swine | 1 | 1993 | 761 | 0.020 |
Why?
| | Polytetrafluoroethylene | 2 | 2003 | 24 | 0.020 |
Why?
| | Mice | 2 | 2024 | 16983 | 0.020 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 83 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2009 | 62 | 0.020 |
Why?
| | Infant | 1 | 2023 | 9018 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2010 | 318 | 0.020 |
Why?
| | Probability | 1 | 2010 | 304 | 0.020 |
Why?
| | Morbidity | 1 | 2009 | 302 | 0.020 |
Why?
| | Medicare | 1 | 2014 | 719 | 0.020 |
Why?
| | Advisory Committees | 1 | 2009 | 216 | 0.020 |
Why?
| | Suture Techniques | 1 | 2008 | 118 | 0.020 |
Why?
| | Postoperative Hemorrhage | 1 | 2008 | 88 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 998 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2010 | 527 | 0.020 |
Why?
| | Catheterization | 1 | 2007 | 176 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5437 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3062 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2271 | 0.020 |
Why?
| | Pyelonephritis, Xanthogranulomatous | 1 | 2004 | 2 | 0.010 |
Why?
| | Ligation | 1 | 2004 | 87 | 0.010 |
Why?
| | Thrombectomy | 1 | 2004 | 58 | 0.010 |
Why?
| | Escherichia coli Infections | 1 | 2004 | 108 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2004 | 213 | 0.010 |
Why?
| | Washington | 1 | 2003 | 149 | 0.010 |
Why?
| | Hospitalization | 1 | 2012 | 2079 | 0.010 |
Why?
| | Adolescent | 2 | 2006 | 20451 | 0.010 |
Why?
| | Popliteal Vein | 1 | 2001 | 4 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1724 | 0.010 |
Why?
| | Protein S Deficiency | 1 | 2001 | 7 | 0.010 |
Why?
| | Antithrombin III Deficiency | 1 | 2001 | 5 | 0.010 |
Why?
| | Protein C Deficiency | 1 | 2001 | 8 | 0.010 |
Why?
| | Trismus | 1 | 2001 | 2 | 0.010 |
Why?
| | Hospital Charges | 1 | 2001 | 42 | 0.010 |
Why?
| | Causality | 1 | 2001 | 117 | 0.010 |
Why?
| | Cellulitis | 1 | 2001 | 49 | 0.010 |
Why?
| | Child, Preschool | 1 | 1995 | 10522 | 0.010 |
Why?
| | Obesity, Morbid | 1 | 2004 | 242 | 0.010 |
Why?
| | Radiotherapy Dosage | 1 | 2001 | 251 | 0.010 |
Why?
| | Creatine Kinase | 1 | 2000 | 75 | 0.010 |
Why?
| | Eye Diseases | 1 | 2001 | 82 | 0.010 |
Why?
| | Necrosis | 1 | 2001 | 234 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2001 | 377 | 0.010 |
Why?
| | Anesthesia, General | 1 | 2000 | 60 | 0.010 |
Why?
| | Isoenzymes | 1 | 2000 | 301 | 0.010 |
Why?
| | Rectum | 1 | 2000 | 170 | 0.010 |
Why?
| | Myocardial Ischemia | 1 | 2000 | 259 | 0.010 |
Why?
| | Cardiopulmonary Bypass | 1 | 2000 | 203 | 0.010 |
Why?
| | Blindness | 1 | 1998 | 38 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2001 | 1201 | 0.010 |
Why?
| | Drug Evaluation | 1 | 1997 | 82 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2001 | 1282 | 0.010 |
Why?
| | Electrocardiography | 1 | 2000 | 613 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1998 | 224 | 0.010 |
Why?
| | Decision Making | 1 | 2003 | 864 | 0.010 |
Why?
| | Child | 1 | 1995 | 20962 | 0.010 |
Why?
| | Heparin | 1 | 1997 | 254 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1617 | 0.010 |
Why?
| | Hemorrhage | 1 | 1998 | 680 | 0.010 |
Why?
| | Smoking | 1 | 1998 | 1502 | 0.010 |
Why?
|
|
Matsumura's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|